Overview

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Women With Recurrent, or Metastatic Cervical Cancer

Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of QL1706 Plus Chemotherapy in Women With Recurrent, or Metastatic Cervical Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.